Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ASPARAGINASE Cause Second primary malignancy? 50 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 50 reports of Second primary malignancy have been filed in association with ASPARAGINASE (Rylaze). This represents 1.0% of all adverse event reports for ASPARAGINASE.

50
Reports of Second primary malignancy with ASPARAGINASE
1.0%
of all ASPARAGINASE reports
23
Deaths
17
Hospitalizations

How Dangerous Is Second primary malignancy From ASPARAGINASE?

Of the 50 reports, 23 (46.0%) resulted in death, 17 (34.0%) required hospitalization, and 5 (10.0%) were considered life-threatening.

Is Second primary malignancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ASPARAGINASE. However, 50 reports have been filed with the FAERS database.

What Other Side Effects Does ASPARAGINASE Cause?

Febrile neutropenia (557) Neutropenia (322) Bacterial infection (295) Off label use (267) Secondary immunodeficiency (233) Viral infection (228) Clostridium difficile colitis (213) Pyrexia (204) Sepsis (200) Pneumonia (196)

What Other Drugs Cause Second primary malignancy?

CYCLOPHOSPHAMIDE (1,247) DOXORUBICIN (1,151) VINCRISTINE (908) IMATINIB (763) PALBOCICLIB (658) RITUXIMAB (646) RUXOLITINIB (611) ETOPOSIDE (573) PREDNISONE (517) OCTREOTIDE (496)

Which ASPARAGINASE Alternatives Have Lower Second primary malignancy Risk?

ASPARAGINASE vs ASPARAGINASE ERWINIA CHRYSANTHEMI ASPARAGINASE vs ASPARAGINASE ERWINIA CHRYSANTHEMI -RYWN ASPARAGINASE vs ASPIRIN ASPARAGINASE vs ASPIRIN DL-LYSINE ASPARAGINASE vs ASPIRIN LYSINE

Related Pages

ASPARAGINASE Full Profile All Second primary malignancy Reports All Drugs Causing Second primary malignancy ASPARAGINASE Demographics